Biotech's 2004 IPO Hopefuls Expecting Large Step-ups
This article was originally published in Start Up
Executive Summary
Biotech companies waiting in the IPO pipeline have one thing in common: on average, they're expecting step-ups far in excess of those for companies which have already gone public this year.
You may also be interested in...
Biotech's New Breed of IPOs
In assessing the sixteen biotechs making their public debuts over the past six months, investors clearly favor companies specializing in development, not discovery. What's more, investors especially prefer those development firms with late-stage products, lots of cash, and possibly even a sizable out-licensing deal.
Which Private Investors are Cashing Out?
Every venture capitalist is anxious to use the latest IPO window to get his companies liquid. But some firms are more successful than others. At the top of the list there were few surprises--JP Morgan Partners and Alta Partners, with six biotech IPOs each, and MPM Capital with five. But the next group down contained some newer names.